We’ve been discussing this paper for weeks. Now the phase 3 trial in @natureportfolio.nature.com carries an editor’s note after concerns raised online - “social media peer review” 🚩🚩 🔎 Social media amplification requires critical judgment

Honoured to join @JNCI_NOW as Social Media Editor 🚀 Excited to contribute to the digital voice of JNCI Journals and help amplify clinically relevant research with global impact. Scientific publishing is evolving and context & community matter more than ever #Oncology #SciComm

Does TIGIT benefit no one… Or does it benefit a biologically defined subset we failed to identify? 🤔 All-comers trials and conventional biomarkers ignore heterogeneous tumour immune contexts. Is it time for true precision IO? 🔬 #ImmunoOncology #PrecisionMedicine #Biomarkers

New here on Bluesky 🚀 Medical oncologist focused on clinical research, IO and translational science #Oncology #TranslationalResearch #Cancer